Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease?

Nephrology Dialysis Transplantation

Volumn 26, Issue 2, 2011, Pages 670-677

  Paoletti, Ernesto ^a   Bellino, Diego ^a   Gallina, Anna Maria ^a   Amidone, Marco ^a   Cassottana, Paolo ^a   Cannella, Giuseppe ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

chronic kidney disease; dialysis; left ventricular hypertrophy; mortality; outcome

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CHRONIC KIDNEY DISEASE; DIABETIC PATIENT; DIALYSIS; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RISK FACTOR;

AGED; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS;

EID: 79551502744     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq409     Document Type: Article

References (34)

1. Hallan SI, Coresh J, Astor BC et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-2284
2. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047 (Pubitemid 350074801)
3. Stevens PE, O'Donoghue DJ, de Lusignan S et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007; 72: 92-99
4. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663
5. Taal MW, Brenner BM. Renal risk scores: progress and prospects. Kidney Int 2008; 73: 1216-1219
6. Ishani A, Grandits GA, Grimm RH et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor interventional trial. J Am Soc Nephrol 2006; 17: 1444-1452
7. van der Velde M, Halbesma N, de Charro FT et al. Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol 2009; 20: 852-862
8. Hallan SI, Ritz E, Lydersen S et al. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009; 20: 1069-1077
9. Iseki K, Kinjo K, Iseki C et al. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004; 44: 806-814
10. Lea J, Greene T, Hebert L et al. The relationship between magnitude of proteinuria reduction and the risk of end-stage renal disease: results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2005; 165: 947-953
11. Crowe E, Halpin D, Stevens P. Guideline Development Group. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ 2008; 337: a153
12. Paoletti E, Bellino D, Cassottana P et al. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 2005; 46: 320-327
13. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. Lancet 1988; 2: 397
14. National Kidney Foundation: K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive agents in Chronic Kidney Disease. Am J Kidney Dis 2004; 43: S1-S290
15. Sahn DJ, De Maria A, Kisslo J et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083
16. Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necroscopy findings. Am J Cardiol 1986; 57: 450-458
17. Ganau A, Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-1558
18. Parfrey PS, Foley RN, Harnett JD et al. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 1996; 11: 1277-1285
19. Levey AS, Greene T, Kusek JWet al. A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000; 11: A0828
20. Levy D, Garrison RJ, Savage DD et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566
21. London GM, Pannier B, Guerin AP et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12: 2759-2767
22. Paoletti E, Cassottana P, Bellino D et al. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis 2002; 40: 728-736
23. Olsen MH, Wachtell K, Borch-Johnsen K et al. A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention for Endpoint Reduction. J Hum Hypertens 2002; 16: 591-595
24. Spanaus KS, Kronenberg S, Ritz E et al. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem 2007; 53: 1264-1272
25. Dieplinger B, Mueller T, Kollerits B et al. Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD Study. Kidney Int 2009; 75: 408-414
26. de Simone G, Kitzman DW, Palmieri Vet al. Association of inappropriate left ventricular mass with systolic and diastolic dysfunction. The HyperGEN Study. Am J Hypertens 2004; 17: 828-833
27. Drazner MH, Rame JE, Marino EK et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years. The Cardiovascular Health Study. J Am Coll Cardiol 2004; 43: 2207-2215
28. Schrier RW. Role of diminished renal function in cardiovascular mortality. J Am Coll Cardiol 2006; 47: 1-8
29. Zoccali C, Benedetto FA, Tripepi G et al. Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study. J Am Soc Nephrol 2006; 17: 1460-1465
30. Marchais SJ, Guerin AP, Pannier BM et al. Wave reflections and cardiac hypertrophy in chronic uremia: influence of body size. Hypertension 1993; 22: 876-883
31. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney. Cause and logic of therapy. Hypertension 2005; 46: 200-204
32. Roger SD, McMahon LP, Clarkson A et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-156
33. Khan IA, Fink J, Nass C et al. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 2006; 97: 1530-1534
34. Wang AY, Lam CW, Wang M et al. Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients. Nephrol Dial Transplant 2009; 24: 1962-1969